SBIR Topic 241 Phase II: Platelet-based Nanoparticle Therapy for Prostate Cancer
SBIR Topic 241 Phase II: Platelet-based Nanoparticle Therapy for Prostate Cancer
批准号:
8164221
负责人:
MICHAEL ZWICK
金额:
$99.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2012-09-29
中文摘要
该II期计划的目标是开发针对前列腺癌血管成像、组织消融和释放治疗模式的定向能量转移方法。该平台技术是一种冷冻干燥的人类血小板(Stasix颗粒),其中含有超顺磁性氧化铁(SPIO)纳米颗粒。I期研究表明,SPIO-Stasix颗粒在免疫功能低下的小鼠宿主上选择性地定位于人前列腺异种移植物中受损的血管。我们建议进一步验证装载氧化铁的人血小板产品作为成像和治疗方式的递送载体的使用;利用噬菌体展示技术增强人血小板纳米颗粒或合成微装置对前列腺癌微血管的靶向作用;研究表明,靶向前列腺微血管的纳米器件可以启动靶向热致前列腺损伤;并在临床试验中验证和测试雄激素剥夺治疗前列腺癌患者的治疗窗口。本研究全面描述了热疗和造影剂对前列腺微血管的靶向、成像和输送作为前列腺癌治疗和诊断的工具。
英文摘要
The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super paramagnetic iron oxide (SPIO) nanoparticles. The Phase I program showed that SPIO-Stasix particles selectively localize to damaged vasculature in human prostate xenografts on immunocompromised mouse hosts. We propose to further validate the use of human platelet products loaded with iron oxides as delivery vehicles for imaging and therapeutic modalities; to use phage display technology to enhance the targeting of human platelet nanoparticles or synthetic microdevices to prostate cancer microvasculature; to demonstrate that nanodevices targeted to prostate microvasculature can initiate targeted heat-induced damage of the prostate; and to validate and test in clinical trials the therapeutic window induced by androgen deprivation therapy in prostate cancer patients. This proposal represents a full characterization of the targeting, imaging and delivery of heat therapy and contrast agents to prostate microvasculature as a tool for the treatment and diagnosis of prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金